Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,341.00DKK
6:03am EDT
Change (% chg)

kr.-19.00 (-1.40%)
Prev Close
kr.1,360.00
Open
kr.1,354.00
Day's High
kr.1,358.00
Day's Low
kr.1,337.00
Volume
63,063
Avg. Vol
223,976
52-wk High
kr.1,489.00
52-wk Low
kr.970.00

GEN.CO

Chart for GEN.CO

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.24
Market Cap(Mil.): kr.83,121.02
Shares Outstanding(Mil.): 61.12
Dividend: --
Yield (%): --

Financials

  GEN.CO Industry Sector
P/E (TTM): 62.19 79.56 32.84
EPS (TTM): 21.87 -- --
ROI: 29.46 2.86 14.86
ROE: 29.47 5.27 16.11

RPT-BRIEF-Genmab CEO confident to close some tech deals this year

Aug 9 GENMAB'S CEO JAN VAN DE WINKEL SAYS IN TELEPHONE INTERVIEW WITH REUTERS:

Aug 10 2017

BRIEF-Genmab CEO confident to close some tech deals this year

Aug 9 GENMAB'S CEO JAN VAN DE WINKEL SAYS IN TELEPHONE INTERVIEW WITH REUTERS:

Aug 09 2017

BRIEF-Genmab Q2 net profit at DKK 307.3 million

* SAYS ‍REVENUE WAS DKK 1,024 MILLION IN FIRST HALF OF 2017 COMPARED TO DKK 524 MILLION IN FIRST HALF OF 2016​

Aug 09 2017

BRIEF-Genmab reports Q2 net sales of Darzalex

* Genmab announces net sales of Darzalex® (daratumumab) for second quarter of 2017 Source text for Eikon: Further company coverage:

Jul 18 2017

BRIEF-Genmab: net sales of DARZALEX in Q2 totaled USD 299 mln

* GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR SECOND QUARTER OF 2017

Jul 18 2017

BRIEF-Genmab says U.S. FDA approves darzalex in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

* Genmab announces u.s. fda approval of darzalex(daratumumab) in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

Jun 16 2017

BRIEF-Genmab announces plans for new studies of Daratumumab

* Genmab says 3 new phase iii studies of daratumumab planned in multiple myeloma and amyloidosis

May 17 2017

BRIEF-Genmab Q1 oper profit DKK 46 million; above expectations

* Q1 USD 255 MILLION IN NET SALES OF DARZALEX® (DARATUMUMAB); RESULTING IN ROYALTY INCOME OF DKK 211 MILLION

May 10 2017

BRIEF-Genmab announces new late stage combination study of Daratumumab in multiple myeloma

* Genmab announces new phase III combination study of Daratumumab in multiple myeloma

Apr 28 2017

BRIEF-Genmab announces new Phase III combination study of Daratumumab

* GENMAB ANNOUNCES NEW PHASE III COMBINATION STUDY OF DARATUMUMAB IN MULTIPLE MYELOMA

Apr 28 2017

Earnings vs. Estimates